A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03450915|
Recruitment Status : Completed
First Posted : March 1, 2018
Results First Posted : September 13, 2021
Last Update Posted : October 5, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Influenza||Biological: M-001 Biological: Saline||Phase 3|
The placebo-controlled pivotal clinical efficacy Phase 3 trial plans to enroll a total of approximately 12,460 participants over two years. Participants will be immunized twice with the M-001 influenza vaccine candidate or placebo. Influenza incidence and illness severity will be evaluated throughout the follow-up period of up to two years. Participants will be 50 years and older, with at least half over 65 years of age.
The trial is expected to take place in eastern European countries and begin prior to the 2018/19 Northern Hemisphere flu season.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12460 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Experimental group: 2 immunizations with M-001 Control group: 2 injection of saline (placebo)|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||All parties are blinded except for the person who prepares the syringe for injection. The M-001 is cloudy white and its appearance is different from the transparent saline that is used for placebo. The person prepares the syringe with an opaque sticker that fully covers the syringe contents. People administering the syringe are not involved or present during syringe preparation, and are thus fully blinded.|
|Official Title:||A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).|
|Actual Study Start Date :||August 1, 2018|
|Actual Primary Completion Date :||July 2, 2020|
|Actual Study Completion Date :||October 23, 2020|
Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
Other Name: Multimeric-001
Placebo Comparator: Saline
Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
0.9% sodium chloride (NaCl)
- Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness [ Time Frame: From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year ]Prevention of influenza disease by comparing the occurrence of either qRT-PCR or culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.
- Number of Participants With One or More Serious Adverse Events, New Onset Chronic Illness, and Non-solicited Adverse Events [ Time Frame: From Day 0 to end of study completion by participant which coincides with end of flu season in the respective year, an average of 4 months per participant per year ]Number of participants with one or more Serious Adverse Events, New Onset Chronic illness, and Non-solicited Adverse Events assessed during one flu season per participant
- Number of Participants With Culture-confirmed Influenza Incidence [ Time Frame: From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year ]Occurrence of culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.
- Number of Participants With Reduction of Severity of qRT-PCR or Culture-confirmed Influenza [ Time Frame: From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year ]Assessed by reduction of severity of either qRT-PCR or culture-confirmed influenza illness by the reduction due to M-001 in the average number of days with respiratory or systemic symptoms during the first laboratory-confirmed influenza illness episode.
- Number of Participants With Influenza-like Illness Symptoms [ Time Frame: From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year ]Assessment of number of participants having ILI symptoms in the experimental or control group
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Male and female subjects 50 years of age (inclusive) or older, mentally competent, willing and able to give the written informed consent prior to study entry
- Able to comply with the trial procedures and be available for all study visits.
- Medically stable. (Subjects may have underlying chronic conditions such as hypertension, diabetes, ischemic heart disease, or hypothyroidism, as long as their symptoms/signs are controlled. If they are on medication for a condition, the medication dose must have been stable for at least 3 months preceding vaccination).
- Women of childbearing potential (not surgically sterile or postmenopausal for greater than or equal to one year) and men must agree to practice adequate contraception (barrier or hormone methods or intra uterine device (IUD) for women and a condom for men) throughout the study treatment and for at least up to day 51 (for female) and day 111 (for male) of the trial (i.e. 30 (for female) and 90 (for male) days after the last dose of the IMP)
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination.
- History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine.
- Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age).
- Receipt of: a) Immunosuppressive drugs: i) systemic glucocorticoids >/= 10 mg prednisone per day ii) cytotoxic drugs b) Investigational drugs within 30 days before, or planned during, the study c) Blood products within 3 months before, or planned during, the study d) Influenza vaccine within 6 months before the study) Other vaccines within 30 days before, or planned during, the study
- Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, or congestive heart failure, as judged by the PI.
- An acute illness, including an axillary temperature greater than 38 Celsius (38ºC), occurred within 1 week before first vaccination
- Positive positive urine pregnancy test prior to vaccination or women who are breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03450915
|Jagiellońskie Centrum Innowacji Sp.z o.o.|
|Kraków, Ul. Bobrzyńskiego 14,, Poland, 30-348|
|Jagiellońskie Centrum Innowacji Sp.z o.o.|
|Kraków, Poland, 30348|
|Study Director:||Tamar Ben-Yedidia, PhD||BiondVax Pharmaceuticals ltd.|
Documents provided by BiondVax Pharmaceuticals ltd.:
|Responsible Party:||BiondVax Pharmaceuticals ltd.|
|Other Study ID Numbers:||
|First Posted:||March 1, 2018 Key Record Dates|
|Results First Posted:||September 13, 2021|
|Last Update Posted:||October 5, 2021|
|Last Verified:||September 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases